Prognostic factors for mature natural killer (NK) cell neoplasms: aggressive NK cell leukemia and extranodal NK cell lymphoma, nasal type

Suzuki, Ritsuro; Suzumiya, Junji; Yamaguchi, Motoko; Nakamura, Shigeo; Kameoka, Junichi; Kojima, Hiroshi; Abe, Masafumi; Kinoshita, Tomohiro; Yoshino, Tadashi; Iwatsuki, Keiji; Kagami, Yoshitoyo; Tsuzuki, Toyonori; Kurokawa, Mineo; Ito, Kei; Kawa, Keisei; Oshimi, Kazuo

doi:10.1093/annonc/mdp418

Cited by 231 publications

(220 citation statements)

References 53 publications

Supporting

Mentioning

202

Contrasting

Unclassified

Order By: Relevance

“…There is circulating EBV DNA and evidence that patients with higher titers have a poorer prognosis [35]. Patients with local/regional disease involving the nose and nasal sinuses have the best outlook, whereas patients who present in other sites and have wide-spread disease have an extremely poor outlook with therapies applied to date [36].…”

Section: Nk/t-cell Lymphomamentioning

confidence: 99%

“…Obviously, involved field radiotherapy would have no chance to be curative in these patients. Typical anthrocycline-containing chemotherapy regimens have yielded poor results, with few patients have extended survival [36]. This may be, in part, because these tumors express Pglycoprotein and have the multidrug resistance phenotype [85].…”

Section: Nk/t-cell Lymphomamentioning

confidence: 99%

See 1 more Smart Citation

The aggressive peripheral T‐cell lymphomas: 2015

Armitage

2015

American J Hematol

View full text Add to dashboard Cite

Background: T‐cell lymphomas make up approximately 10%–15% of lymphoid malignancies. The frequency of these lymphomas varies geographically, with the highest incidence in parts of Asia.Diagnosis: The diagnosis of aggressive peripheral T‐cell lymphoma (PTCL) is usually made using the World Health Organization classification. The ability of hematopathologists to reproducibly diagnosis aggressive PTCL is lower than that for aggressive B‐cell lymphomas, with a range of 72%–97% for the aggressive PTCLs.Risk Stratification: Patients with aggressive PTCL are staged using the Ann Arbor Classification. Although somewhat controversial, positron emission tomography scans seem to be useful as they are in aggressive B‐cell lymphomas. The most commonly used prognostic index is the International Prognostic Index. The specific subtype of aggressive PTCL is an important risk factor, with the best survival seen in anaplastic large‐cell lymphoma—particularly young patients with the anaplastic lymphoma kinase positive subtype.Risk‐Adapted Therapy: Anaplastic large‐cell lymphoma is the only subgroup to have a good response to a CHOP‐like regimen. Angioimmunoblastic T‐cell lymphoma has a prolonged disease‐free survival in only ∼20% of patients, but younger patients who have an autotransplant in remission seem to do better. PTCL‐not otherwise specified is not one disease. Anthracycline‐containing regimens have disappointing results, and a new approach is needed. Natural killer/T‐cell lymphoma localized to the nose and nasal sinuses seems to be best treated with radiotherapy‐containing regimens. Enteropathy‐associated PTCL and hepatosplenic PTCL are rare disorders with a generally poor response to therapy, although selected patients with enteropathy‐associated PTCL seem to benefit from intensive therapy. Am. J. Hematol. 90:666–673, 2015. © 2015 Wiley Periodicals, Inc.

show abstract

Section: Nk/t-cell Lymphomamentioning

confidence: 99%

Section: Nk/t-cell Lymphomamentioning

confidence: 99%

The aggressive peripheral T‐cell lymphomas: 2015

Armitage

2015

American J Hematol

View full text Add to dashboard Cite

show abstract

“…Two-thirds of patients have localized disease in the upper aero-digestive tract [15,16], which has been referred to as nasal NKTCL [1]. Radiotherapy (RT) is believed to be a key treatment modality for this population, as the complete response (CR) rate from RT alone is [65 % [17, 18].…”

Section: Specific Factors In Clinical Trials For Localized Enklmentioning

confidence: 99%

“…The relative incidence of advanced NKTCL among all cases of ENKL is approximately 30 % [16,27,28]. Patients with disseminated disease often represent impaired organ function due to the disease.…”

Section: Specific Factors In Trials For Disseminated Enklmentioning

confidence: 99%

Current and future management of NK/T-cell lymphoma based on clinical trials

Yamaguchi

2012

Int J Hematol

View full text Add to dashboard Cite

Recently reported results of well-designed prospective clinical trials for extranodal NK/T-cell lymphoma, nasal type (ENKL) have rapidly changed the management of ENKL. This review will focus on the evidence obtained from prospective clinical trials for ENKL and discuss the most highly recommended current management and future directions for the better management of ENKL. For patients with nasal NK/T-cell lymphoma of stage IE or contiguous stage IIE with cervical node involvement, concurrent chemoradiotherapy with radiotherapy (RT) and a two-thirds dose of DeVIC chemotherapy is recommended as a first-line treatment. To obtain the expected clinical outcome, performing RT following the same procedure as that reported is important. For the other patients with newly diagnosed ENKL, SMILE chemotherapy is recommended as an induction therapy. The Epstein-Barr virus DNA load in peripheral blood is useful for both prognostication and monitoring during the follow-up after treatment. Other L-asparaginasecontaining chemotherapies and chemotherapies containing non-multidrug resistance-related agents and etoposide are good options for elderly patients or patients with impaired organ function. As in the cases of other aggressive lymphomas, prospective clinical trials with adequate statistical considerations should be conducted to improve the prognosis of patients with ENKL.

show abstract

“…Extranodal NK/T-cell lymphoma, nasal type, is pathogenetically related to EBV, showing a complex geographic and racial increased prevalence in East Asians and indigenous peoples of Mexico, Central and South America. [100][101][102][103] Tumors most commonly present with obstruction and central destruction or perforation of the nasal cavity and paranasal sinuses, [104][105][106] most patients presenting with low stage I or II disease.…”

Section: Nut Carcinoma (Squamous Cell Carcinoma)mentioning

confidence: 99%

Small round blue cell tumors of the sinonasal tract: a differential diagnosis approach

Thompson

2017

Modern Pathology

View full text Add to dashboard Cite

One of the most challenging diagnostic categories within tumors of the sinonasal tract is the small round blue cell tumors. Biopsies are usually small and limited, resulting in considerable diagnostic difficulty for practicing surgical pathologists. These tumors share several overlapping histologic and immunophenotypic findings while also showing considerable variation within and between cases. Specific tumor site of origin, imaging findings, and clinical findings must be combined with the histology and pertinent ancillary studies if the correct diagnosis is to be reached. Discrimination between neoplasms is critical as there are significant differences in therapy and overall outcome. It is important to have a well developed differential diagnosis for this category of tumors, where each of the diagnoses is considered, evaluated, and either confirmed or excluded from further consideration. In an undifferentiated tumor, showing a small round blue cell morphology, using the mnemonic 'MR SLEEP' helps to highlight tumors to consider: melanoma, mesenchymal chondrosarcoma, rhabdomyosarcoma, sinonasal undifferentiated carcinoma, squamous cell carcinoma (including NUT carcinoma), small cell osteosarcoma, lymphoma, esthesioneuroblastoma (olfactory neuroblastoma), Ewing sarcoma/primitive neuroectodermal tumor, pituitary adenoma, and plasmacytoma. A panel of pertinent immunohistochemistry studies, histochemistries and/or molecular tests should aid in reaching a diagnosis, especially when taking the pattern and intensity of reactions into consideration.

show abstract

Prognostic factors for mature natural killer (NK) cell neoplasms: aggressive NK cell leukemia and extranodal NK cell lymphoma, nasal type

Abstract: The current prognostic model successfully stratified patients with NK cell neoplasms with different outcomes.

Cited by 231 publications

References 53 publications

The aggressive peripheral T‐cell lymphomas: 2015

The aggressive peripheral T‐cell lymphomas: 2015

Current and future management of NK/T-cell lymphoma based on clinical trials

Small round blue cell tumors of the sinonasal tract: a differential diagnosis approach

Contact Info

Product

Resources

About